Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Return on Capital Employed came in at 14.2% in Q1 2026, up 19.0% year-on-year from 11.94% in Q1 2025, and down 65.05% on a QoQ basis from 40.64% in Q4 2025.
Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of Return on Capital Employed data on file, last reported at 14.2% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 19.0% year-over-year to 14.2% in Q1 2026; TTM through Mar 2026 was 14.2%, a 19.0% increase from a year earlier, with the FY2025 full-year figure at 28.22%, up 583.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 14.2%, down from 40.64% in the prior quarter.
- Over the last five years, Return on Capital Employed for SLGL reached as high as 50.03% in Q1 2022 and fell as low as 30.85% in Q1 2024.
- Historically, Return on Capital Employed has averaged 11.05% across 5 years, with a median of 5.84% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 5711 bps in 2022 and fell as far as 6324 bps in 2022.
- Year by year, Return on Capital Employed stood at 7.49% in 2022, then plunged by 123 bps to 16.67% in 2023, then soared by 125 bps to 4.13% in 2024, then soared by 884 bps to 40.64% in 2025, then plunged by 65 bps to 14.2% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 14.2% in Q1 2026, 40.64% in Q4 2025, and 25.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | 14.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.20% |
| Dec 31, 2025 | 40.64% |
| Sep 30, 2025 | 25.69% |
| Jun 30, 2025 | 47.37% |
| Mar 31, 2025 | 14.01% |
| Dec 31, 2024 | 4.13% |
| Sep 30, 2024 | 5.84% |
| Jun 30, 2024 | -9.45% |
| Mar 31, 2024 | -30.85% |
| Dec 31, 2023 | -16.67% |
| Sep 30, 2023 | -16.63% |
| Jun 30, 2023 | -11.41% |
| Mar 31, 2023 | 3.86% |
| Dec 31, 2022 | -7.49% |
| Sep 30, 2022 | 33.14% |
| Jun 30, 2022 | 41.39% |
| Mar 31, 2022 | 50.03% |
| Dec 31, 2021 | 55.76% |
| Sep 30, 2021 | 17.10% |
| Jun 30, 2021 | -7.11% |